**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 78555

**Manuscript Type:** CASE REPORT

**Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report**

Liu XH *et al*. Primary squamous cell carcinoma: Sarcomatoid

Xue-Hua Liu, Qian-Ming Zou, Jia-Dong Cao, Zhi-Chao Wang

**Xue-Hua Liu, Qian-Ming Zou, Jia-Dong Cao, Zhi-Chao Wang,** Department of Urology Surgery, Fangcun Hospital of Guangdong Provincial Hospital of traditional Chinese Medicine, Guangzhou 510120, Guangdong Province, China

**Author contributions:** Liu XH conducted the literature search, collected data, interpreted the data, and prepared the manuscript; Zou QM collected data, interpreted the data, edited the manuscript, and critically revised the draft; Cao JD interpreted the data and critically revised the draft; Wang ZC designed the study, interpreted the data, edited the manuscript, and critically revised the draft; all authors have read and approved the final version to be published.

**Corresponding author: Zhi-Chao Wang, MD, Attending Doctor,** Department of Urology Surgery, Fangcun Hospital of Guangdong Provincial Hospital of traditional Chinese Medicine, NO. 36 Lihai Road, Liwan District, Guangzhou 510120, Guangdong Province, China. 13602495696@163.com

**Received:** July 3, 2022

**Revised:** September 2, 2022

**Accepted:** October 11, 2022

**Published online:** November 16, 2022

**Abstract**

BACKGROUND

Primary squamous cell carcinoma (SCC) with sarcomatoid differentiation of the kidney was rarely reported. This disease is usually related to renal stones, and due to a lack of symptoms and radiological features, patients usually attend the hospital with late stage disease.

CASE SUMMARY

A 54-years-old female presented with left flank pain and an abdominal mass for 6 mo. Imaging studies revealed that the left kidney was enlarged and massive hydronephrosis was present. A stone was seen in the ureteropelvic junction. The patient subsequently underwent left radical nephrectomy, and histopathological examination of the mass revealed a poorly differentiated renal SCC with sarcomatoid differentiation. After primary surgery, the patient received four cycles of tirelizumab. Four months later, the patient developed adrenal, lymph, and uterine appendage metastases.

CONCLUSION

SCC of the kidney has a poor prognosis, and should be considered in patients with a renal mass, long-standing urinary calculi and massive hydronephrosis.

**Key Words:** Squamous cell carcinoma; Sarcomatoid differentiation; Kidney; Ureteral stone; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Liu XH, Zou QM, Cao JD, Wang ZC. Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report. *World J Clin Cases* 2022; 10(32): 11942-11948

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i32/11942.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i32.11942

**Core Tip:** Squamous cell carcinoma (SCC) with sarcomatoid differentiation is extremely rare and has a poor prognosis. The presence of SCC should be considered when a renal mass is found in a patient with long-term stones and hydronephrosis. Early surgical treatment may be beneficial.

**INTRODUCTION**

Primary squamous cell carcinoma (SCC) of the kidney is a rare cancer with a poor prognosis at the time of presentation[1]. Renal SCC with sarcomatoid differentiation is a rare condition. To date, there has been only one report of SCC of the renal pelvis with sarcomatoid differentiation[2]. We report a case of primary renal SCC with sarcomatoid differentiation, associated with ureteral stones and severe hydronephrosis.

**CASE PRESENTATION**

***Chief complaints***

A 54-year-old female patient presented to the hospital with flank pain and an abdominal mass for 6 mo.

***History of present illness***

The patient presented with flank pain and an abdominal mass for 6 mo which had become worse in the previous 2 wk.

***History of past illness***

The patient had no history of any other diseases, and had no history of surgery.

***Personal and family history***

The patient had previous normal menstruation, but was now menopausal. She denied any relevant family history.

***Physical examination***

General and physical examination results were normal. Abdominal examination revealed a large mass in the left abdomen.

***Laboratory examinations***

The patient’s serum urea and creatinine levels were 3.37 mmol/L and 67 μmol/L, respectively. Urine examination revealed hematuria (grade 1+).

***Imaging examinations***

Ultrasound showed that the left kidney was enlarged with severe hydronephrosis and a thin renal parenchyma. A stone measuring approximately 8 mm was observed in the ureteropelvic junction. Two round masses were observed in the middle and upper parts of the left kidney. Abdominal computed tomography (CT) revealed an 8-mm stone in the left upper ureter (Figure 1A), and severe hydronephrosis was seen in the left kidney. The masses detected in the left renal parenchyma were quasi-circular, uneven, and had a slightly low-density shadow and uneven enhancement, and the largest measured approximately 9 cm × 10 cm (Figure 1B).

***Further diagnostic work-up***

A left radical nephrectomy was subsequently performed. Gross examination of the radical nephrectomy specimen revealed enlargement of the left kidney. There were several nodules in the renal parenchyma, 20 cm × 13 cm × 10 cm in size, most of which were diffuse flakes, and some were spindle-shaped and fascicular, a small amount of bone-like matrix was also observed. Scattered squamous areas were observed in the diffuse area, along with the formation of keratinized beads.

Microscopic examination revealed SCC of the renal parenchyma with dedifferentiated sarcomatosis (Figure 2). The proportion of sarcomatoid components was approximately 50%.

Immunohistochemistry revealed the following: Creatine kinase (CK) (squamous area +), Epithelial membrane antigen (squamous area +), Cluster of Differentiation (CD)10 (squamous area and diffuse area +), vimentin (squamous area +), CK7 (small focus squamous area +), Melanoma marker (human) monoclonal antibody (HMB45) (-), S100 (-), Carbonic Anhydrase ix (small amount +), Ki67 (hot spot area about 80% +), P40 (small focus squamous area +) (Figure 3A), p63 (squamous area and diffuse area +) (Figure 3B), CK20 (-), p53 (approximately 85% +), GATA-3 (squamous area and diffuse area +), CK18 (small focus squamous area +), Smooth Muscle Actin (-), CD34 (-), and desmin (-).

**FINAL DIAGNOSIS**

Renal SCC with sarcomatoid differentiation.

**TREATMENT**

Following radical nephrectomy, the patient received four cycles of tirelizumab.

**OUTCOME AND FOLLOW-UP**

The patient developed adrenal, lymph, and uterine appendage metastases. Died 7 mo after nephrectomy.

**DISCUSSION**

SCC of the kidney is a very rare malignancy, mostly diagnosed at advanced stages, and represents approximately 1.4% of all renal malignancies[3]. Only a few cases have been reported in the literature; therefore, the data on SCC of the kidney are from a few case reports[4,5]. Squamous cell cancers of the kidney are associated with a poor prognosis. SCC presents with late stage disease and poor survival rates[3]. Some case series have reported a median survival time of 3.5 mo[6]. Renal SCC with sarcomatoid differentiation is even rarer. There is only one other reported case of renal SCC with sarcomatoid differentiation[2]. This case was a 55-years-old female, presented with flank pain and an abdominal mass, CT scan demonstrated gross right renal hydronephrosis with renal parenchymal atrophy and multiple right renal calculi. She accepted open nephrectomy. The pathology suggested that the macroscopic examination showed hydronephrosis with severe pyonephritis, obvious cortical atrophy and obstructive kidney stones at pelviureteric junction. Histological examination unexpectedly revealed squamous metaplasia of pelvic urothelial epithelium with free debris of SCC in situ and sarcomatoid tumors. The five epithelial markers of sarcomatoid tumors were all negative, and only P63 was positive. Two months after the operation, a large mass was found in the original renal fossa. The needle biopsy considered SCC with sarcomatoid transformation. Then she received palliative radiotherapy and died 3 mo after nephrectomy. Our case is similar to this case, the difference is that our case can find obvious tumors on CT.

Renal cell carcinoma (RCC) with sarcomatoid dedifferentiation is usually referred to as sarcomatoid RCC (sRCC), and sRCC often presents at an advanced stage or metastatic disease and patients rarely survive for > 1 year[7].However, of all RCC cases, sarcomatoid features are present in approximately 4%–5%[8]. In 2012, the International Society of Urological Pathology Consensus Conference established that sarcomatoid transformation could be designated within RCC if it included atypical spindle cells and resembled “any form of sarcoma”. To establish the diagnosis of sRCC, no minimum number or percentage of sarcomatoid dedifferentiation is needed. Sarcomatoid dedifferentiation may occur in any RCC subtype. This feature is not considered a unique type but is a high-grade manifestation of the original tumor[9].

Clinically, SCC or sRCC occurs in middle-aged patients with symptoms including flank pain, hematuria, and an abdominal mass, and is often associated with chronic inflammation, hydronephrosis, and squamous metaplasia[10]. In 18%–100% of cases, urolithiasis is a main risk factor[2]. Therefore, it is difficult to differentiate the disease clinically.

Radiologically, primary SCC of the renal pelvis may present as a solid tumor, with renal effusion, calcifications, or as infiltrative lesions of the renal pelvis without obvious masses[11]. The differential diagnosis by radiologic [comprise](file:///C%3A%5CProgram%20Files%5Cbaidu-translate-client%5Cresources%5Capp.asar%5Capp.html#/#) primary and secondary [kidney cancer](file:///C%3A%5CProgram%20Files%5Cbaidu-translate-client%5Cresources%5Capp.asar%5Capp.html#/#) and xanthogranulomatous pyelonephritis (XGP) related to nephrolith. XGP is a rare chronic pyelonephritis, usually occurs in chronic obstruction, resulting in hydronephrosis and destruction of renal parenchyma. XGP is usually related to renal calculus, but rarely causes keratinizing squamous metaplasia, it is very similar to renal tumors, leading to misdiagnosis of malignant tumors[12]. The clinical and radiologic features are inapparent in renal SCC may easy to misdiagnose. Histopathology is required for diagnosis[13].

Histologically, SCC shows extensive squamous differentiation and keratin pearls[14]. sRCCs usually is large (median size approximately 10 cm), the section is white or grayish white, and tough texture[15]. Primary SCC of the renal parenchyma needs to be differentiated from the following diseases: Primary SCC of renal pelvis, distant metastatic SCC, and transitional epithelial carcinoma of the urinary with extensive squamous metaplasia. If there are recognizable immature transitional cell components including urothelial carcinoma in situ, should be classified as primary urothelial carcinoma with squamous differentiation. However, typical keratinizing squamous metaplasia of the adjacent flattened urothelium, especially associated with dysplasia, supports a diagnosis of primary SCC of the renal pelvis[4]. In this case, we don’t found dysplastic urothelial component or squamous metaplasia of urothelium.

Lee *et al*[8] in their study classified these tumors into two groups, according to localisation of the tumors as central and peripheral. Central renal cell carcinoma presents more Intraluminal components and is usually associated with lymph node metastasis whereas peripheral renal SCC presents with prominent renal parenchymal thickening and might invade the perirenal fat tissue before lymph node or distant metastasis could be identified[8]. Based on these criteria the present case classified as central renal SCC.

The prognosis of renal SCC is poor, and most cases are diagnosed in the late, terminal stage. As 60%–80% of sRCC patients present with advanced or terminal stage disease, the natural history and prognosis is bleak[16]. The median survival time is approximately 6–13 mo, and a higher percentage of sarcomatoid dedifferentiation on histology has been reported to confer a worse prognosis[17]. Due to the heterogeneity of tumors, 3D fusion sampling can better grade and stage tumors, better guide clinical adjuvant treatment and evaluate prognosis[18].

Radical nephrectomy is the first choice for patients with tumors limited to the kidney. However, outcomes are less encouraging for patients with localized sRCC, as approximately 77%–80% of patients receiving nephrectomy for localized sRCC relapse within 5–26 mo[19].

sRCC has a poor response to radiotherapy and chemotherapy. Immune checkpoint inhibitors may have some therapeutic effects in the treatment of sRCCs. In pathology, the activation of the Programmeddeath-1 (PD-1) /Programmed Cell Death-Ligand 1 (PD-L1) signaling pathway probably can block immune cell activation, tumor cells may be use this mechanism to escape anti-tumor immune control. Targeting the PD-1/PD-L1 axis is a milestone breakthrough in cancer treatment[20]. Future clinical trials should focus on therapies such as anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4), anti-PDL1, anti-PD1, and combinations with targeted therapy agents that have been shown to augment the cytotoxic tumor immune microenvironment to improve progression and survival outcomes in patients with sRCCs[21,22]. However, as observed in our case, the available medical literature on this rare malignant entity indicates a poor prognosis.

**CONCLUSION**

Renal SCC with sarcomatoid differentiation is extremely rare, and the prognosis is very poor. In patients with renal masses, long-standing urinary calculi and massive hydronephrosis, should be alert to the possibility of renal SCC. Early surgical treatment combined with immunotherapy may provide a survival benefit.

**ACKNOWLEDGEMENTS**

We thank Professor Xiang Song-Tao for his guidance in the study.

**REFERENCES**

1 **Jain A**, Mittal D, Jindal A, Solanki R, Khatri S, Parikh A, Yadav K. Incidentally detected squamous cell carcinoma of renal pelvis in patients with staghorn calculi: case series with review of the literature. *ISRN Oncol* 2011; **2011**: 620574 [PMID: 22091426 DOI: 10.5402/2011/620574]

2 **Shepherd ARH**, Hoh IMY, Goh EH, Cohen PA, Steele D. Aggressive renal tumour: squamous cell carcinoma with sarcomatoid differentiation. *ANZ J Surg* 2017; **87**: 1054-1056 [PMID: 25962888 DOI: 10.1111/ans.13155]

3 **Hosseinzadeh M**, Mohammadzadeh S. Primary Pure Squamous Cell Carcinoma of Kidney Associated with Multiple Stag Horn Stones. *Int Med Case Rep J* 2020; **13**: 261-263 [PMID: 32753979 DOI: 10.2147/IMCRJ.S261022]

4 **Ghosh P**, Saha K. Primary intraparenchymal squamous cell carcinoma of the kidney: a rare and unique entity. *Case Rep Pathol* 2014; **2014**: 256813 [PMID: 24575308 DOI: 10.1155/2014/256813]

5 **Kulshreshtha P**, Kannan N, Bhardwaj R, Batra S. Primary squamous cell carcinoma of the renal parenchyma. *Indian J Pathol Microbiol* 2012; **55**: 370-371 [PMID: 23032834 DOI: 10.4103/0377-4929.101747]

6 **Berz D**, Rizack T, Weitzen S, Mega A, Renzulli J, Colvin G. Survival of patients with squamous cell malignancies of the upper urinary tract. *Clin Med Insights Oncol* 2012; **6**: 11-18 [PMID: 22253551 DOI: 10.4137/CMO.S8103]

7 **Lee TY**, Ko SF, Wan YL, Cheng YF, Yang BY, Huang DL, Hsieh HH, Yu TJ, Chen WJ. Renal squamous cell carcinoma: CT findings and clinical significance. *Abdom Imaging* 1998; **23**: 203-208 [PMID: 9516518 DOI: 10.1007/s002619900324]

8 **Mian BM**, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. *J Urol* 2002; **167**: 65-70 [PMID: 11743277]

9 **Kim T**, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. *Clin Genitourin Cancer* 2015; **13**: 225-230 [PMID: 25544725 DOI: 10.1016/j.clgc.2014.12.001]

10 **Delahunt B**, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. *Am J Surg Pathol* 2013; **37**: 1490-1504 [PMID: 24025520 DOI: 10.1097/PAS.0b013e318299f0fb]

11 **Kalayci OT**, Bozdag Z, Sonmezgoz F, Sahin N. Squamous cell carcinoma of the renal pelvis associated with kidney stones: radiologic imaging features with gross and histopathological correlation. *J Clin Imaging Sci* 2013; **3**: 14 [PMID: 23814686 DOI: 10.4103/2156-7514.109741]

12 **Mardi K**, Kaushal V, Sharma V. Rare coexistence of keratinizing squamous cell carcinoma with xanthogranulomatous pyelonephritis in the same kidney: report of two cases. *J Cancer Res Ther* 2010; **6**: 339-341 [PMID: 21119270 DOI: 10.4103/0973-1482.73351]

13 **Karabulut A,** Emir L, Gonultas M, Incel N, Germiyanoglu C, Erol D. Squamous cell carcinoma located in the renal caliceal system: A case report and review of the literature. *Turk J Cancer* 2002; **32**: 20-24

14 **Odabas O,** Karakok M, Yilmaz Y. Squamous cell carcinoma of kidney. *East J Med* 2000; **5** ( 1 ): 35-56

15 **Diwan AK,** Kabre RS. Primary squamous cell carcinoma of kidney: A rare case report. *Int J Med Sci Res Pract* 2015; **2**: 49-53

16 **Kuroda N**, Toi M, Hiroi M, Enzan H. Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects. *Histol Histopathol* 2003; **18**: 551-555 [PMID: 12647806 DOI: 10.14670/HH-18.551]

17 **Alevizakos M**, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. *Clin Genitourin Cancer* 2019; **17**: e447-e453 [PMID: 30799129 DOI: 10.1016/j.clgc.2019.01.005]

18 **Brunelli M**, Martignoni G, Malpeli G, Volpe A, Cima L, Raspollini MR, Barbareschi M, Tafuri A, Masi G, Barzon L, Ammendola S, Villanova M, Cerruto MA, Milella M, Buti S, Bersanelli M, Fornarini G, Rebuzzi SE, Vellone VG, Gaggero G, Procopio G, Verzoni E, Bracarda S, Fanelli M, Sabbatini R, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Caliò A, Eccher A, Alongi F, Pappagallo G, Iacovelli R, Mosca A, Umari P, Montagnani I, Gobbo S, Atzori F, Munari E, Maruzzo M, Basso U, Pierconti F, Patriarca C, Colombo P, Lapini A, Conti G, Salvioni R, Bollito E, Cossarizza A, Massari F, Rizzo M, Franco R, Zito-Marino F, Aberasturi Plata Y, Galuppini F, Sbaraglia M, Fassan M, Dei Tos AP, Colecchia M, Moch H, Scaltriti M, Porta C, Delahunt B, Giannarini G, Bortolus R, Rescigno P, Banna GL, Signori A, Obispo MAL, Perris R, Antonelli A. Validation of a Novel Three-Dimensional (*3D Fusion*) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. *J Pers Med* 2022; **12** [PMID: 35629151 DOI: 10.3390/jpm12050727]

19 **Adibi M**, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. *Urol Oncol* 2015; **33**: 427.e17-427.e23 [PMID: 26004164 DOI: 10.1016/j.urolonc.2015.04.011]

20 **Munari E**, Mariotti FR, Quatrini L, Bertoglio P, Tumino N, Vacca P, Eccher A, Ciompi F, Brunelli M, Martignoni G, Bogina G, Moretta L. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. *Int J Mol Sci* 2021; **22** [PMID: 34066087 DOI: 10.3390/ijms22105123]

21 **Merrill MM**, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. *Urol Oncol* 2015; **33**: 166.e21-166.e29 [PMID: 25700975 DOI: 10.1016/j.urolonc.2014.11.021]

22 **Tannir NM**, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC, Ficial M, Frontera OA, George S, Powles T, Donskov F, Harrison MR, Barthélémy P, Tykodi SS, Kocsis J, Ravaud A, Rodriguez-Cid JR, Pal SK, Murad AM, Ishii Y, Saggi SS, McHenry MB, Rini BI. Efficacy and Safety of Nivolumab Plus Ipilimumab *vs* Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. *Clin Cancer Res* 2021; **27**: 78-86 [PMID: 32873572 DOI: 10.1158/1078-0432.CCR-20-2063]

**Footnotes**

**Informed consent statement:** The patient provided written informed consent for publication of this report and accompanying images.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 3, 2022

**First decision:** August 21, 2022

**Article in press:** October 11, 2022

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Eccher A, Italy; Patil S, Saudi Arabia **S-Editor:** Liu XF **L-Editor:** A **P-Editor:** Liu XF

**Figure Legends**

****

**Figure 1 Computed tomography.** A: Computed tomography (CT) image showing a ureter stone (arrow); B: CT image showing renal parenchyma masses (arrow).



**Figure 2 Pathological results of renal mass after resection.** A: Squamous cell carcinoma area (hematoxylin-eosin, 400 ×); B: Dedifferentiated sarcomatosis area (hematoxylin-eosin, 400 ×).



**Figure 3 Immunohistochemistry revealed.** A: P40 (small focus squamous area +); B: P63 (squamous area and diffuse area +).



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**